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Abstract
Background: A molecular characterization of Alzheimer’s Disease (AD) is the key to the identification of altered
gene sets that lead to AD progression. We rely on the assumption that candidate marker genes for a given disease
belong to specific pathogenic pathways, and we aim at unveiling those pathways stable across tissues, treatments
and measurement systems. In this context, we analyzed three heterogeneous datasets, two microarray gene
expression sets and one protein abundance set, applying a recently proposed feature selection method based on
regularization.
Results: For each dataset we identified a signature that was successively evaluated both from the computational
and functional characterization viewpoints, estimating the classification error and retrieving the most relevant
biological knowledge from different repositories. Each signature includes genes already known to be related to AD
and genes that are likely to be involved in the pathogenesis or in the disease progression. The integrated analysis
revealed a meaningful overlap at the functional level.
Conclusions: The identification of three gene signatures showing a relevant overlap of pathways and ontologies,
increases the likelihood of finding potential marker genes for AD.
Background
Alzheimer’s Disease (AD) is a common progressive
brain disease generally diagnosed in individuals over 65
years of age and it is mostly characterized by cognition
deterioration that causes dementia [1]. Within 3 to 9
years after diagnosis, it usually leads to death.
From the molecular point of view, AD is characterized
by many different lesions: the most evident are deposits
of beta amyloid and tangles of hyperphosphorylated tau
proteins, together with a marked loss of neurons in the
neocortex and hippocampus [2,3]. In the early stages,
the most common symptom is memory loss, followed
by mood swings, difficult in speech, long-memory loss
and confusion. Several characteristics of AD are com-
mon to normal aging or to other neurological diseases,
making its diagnosis very difficult. Usually, psycho-logi-
cal tests are used to indicate the presence of the disease,
but only a post-mortem exam can confirm it. The
diagnostic process is time-consuming and, by the time
AD is detected, the disease has been progressing for
many years, causing increased brain damages along with
the deterioration of cognitive capacities. For these rea-
sons, AD patients need constant care from their rela-
tives or from specialized structures. Clearly, this
phenomenon has a relevant economical impact on the
national health systems.
Although many scientific papers are published every
year, AD is still a very open research topic and its etiol-
ogy is still unknown. In this context, the mainstream
focus is to understand the underlying molecular
mechanisms with the ultimate goal of identifying poten-
tial biomarkers to be used in the clinical practice.
The basis of our work is the assumption that candi-
date marker genes for a given disease belong to specific
pathogenic pathways. Our aim was to uncover molecular
pathways that are stable across tissues, treatments and
measurement systems. The identification of these path-
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fundamental to unveil those that really feed the progres-
sion of the disease and that might harbor relevant genes.
We considered AD as a case study and obtained
results from the supervised analysis of three publicly
available datasets: one that collects the abundance of
120 signaling proteins [4] and two, retrieved from the
Gene Expression Omnibus (GEO) database, that store
gene expression data from DNA microarray experi-
ments: GSE1297 [5] and GSE5281 [6,7]. The rationale
behind [4] is very convincing and motivated our choice:
since the brain controls many body functions through
the release of signaling proteins in the blood stream, a
brain disease like AD could induce unique changes of
these proteins in the blood. We chose GSE1297 because
it is homogeneous with the protein dataset for the Mini-
Mental State Exam (MMSE) parameter (t-test, p-value <
0.01), which is a 30-points questionnaire test that is
commonly used to screen for cognitive impairment.
Unfortunately, for GSE5281 the MMSE parameter was
not available, but we used it anyway because its plat-
form, i.e. Affymetrix HG-U133 Plus2.0, provides a more
accurate coverage of the human genome and completely
includes the probesets measured with Affymetrix HG-
U133A (GSE1297).
Supervised analysis of high-throughput data allows for
the identification of lists of genes with good prediction
ability. In the remainder of the paper we refer to such
lists as signatures. Gene signature analysis is fundamen-
tal to discover the most relevant functional classes or
biological pathways involved in the progression of
disease.
In this work, we adopted a supervised analysis schema:
l1l2FS regularization with double optimization frame-
work, set in a nested cross-validation structure (l1l2FS).
This method is inspired by [8] and it was recently pro-
ven to be robust and very effective for high-throughput
data analysis [9]. The statistical accuracy of the system
was measured by its prediction error that is the ability
of predicting the outcome on future data (see Materials
and Methods) [10].
By separately applying l1l2FS to each dataset, we
obtained three AD signatures all showing high predic-
tion performances. The small overlap between the two
microarray signatures confirmed the necessity to con-
sider more data coming from the same measuring tech-
nique and also different kind of data in order to
incorporate all the genes that are significantly modu-
lated by the disease.
The analysis was completed by a functional charac-
terization of each signature in the Medical Literature
Analysis and Retrieval System Online (Medline) [11],
Gene Ontology (GO) [12] and the Kyoto Encyclopedia
of Genes and Genomes (KEGG) [13]. This final step
identified a functional overlap of ontologies and
pathways. Even if the majority of the discriminant
genes were different, they were frequently involved in
the same KEGG pathways and/or shared similar GO
ontologies. Moreover, the presence in each signature
of some genes already known to be involved in the dis-
ease confirmed the reliability of the method in select-
ing relevant genes and also increased the likelihood
that the remaining selected genes could be involved in
the development of AD.
Results
The first purpose of this work was to define significant
signatures that are gene or protein lists able to distin-
guish, with a certain degree of reliability, diseased from
control subjects. The second purpose was to test the
biological soundness of the genes selected by the
adopted statistical method. The third and main goal was
to characterize AD at a functional level, identifying
those pathways and functions that are stable across het-
erogeneous data sources.
l1l2FS is a rather novel method for feature selection
and classification but it has recently been applied with
success in the analysis of data coming from high-
throughput techniques [14-17]. We are convinced that
the ability of detecting correlated features is the most
relevant property of l1l2FS, since correlation is a peculiar
and important property characterizing the genes. It is
relevant to note that, in this context, the correlation
parameter μ in l1l2FS is not a threshold value, but it is a
regularization parameter within the naïve elastic net
functional (see Materials and Methods section). It allows
for detecting correlated genes that contribute to the
final outcome in a multivariate fashion.
Our analysis was based on one protein dataset [4] and
two microarray datasets [5,6]. The obtained results are
presented in this order: the classification error estimated
by l1l2FS, a bibliographic (Medline) characterization of
the relevant variables (proteins and probesets) in the sig-
nature, the results of the WebGestalt enrichment analy-
sis performed in KEGG and GO and the analysis of the
significant gene groups identified by the k-means clus-
tering technique. The Medline bibliographic content we
considered relevant concerns: the potential role in AD,
in other brain diseases, in pathways already known to be
related with AD, or the specific expression in some
brain regions. Additional data on the enrichment analy-
sis is available in the Additional files section.
Protein data analysis
Results of the l1l2FS
The analysis of the protein dataset consisted in two
main phases. As shown in Figure 1, we firstly trained
l1l2FS on the Training Set, learning a predictive statistical
model and evaluating a cross-validation error. We then
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assessed the generalization ability of the results on inde-
pendent datasets (Test Set AD and Test Set MCI - Mild
Cognitive Impairment). The algorithm distinguished AD
and control samples with a 10-fold cross-validation
error of 19%. The presented signature corresponds to
the highest value of the correlation parameter μ and it
is composed by 21 genes, reported in Table 1. The fre-
quency score associated to each gene indicates its stabi-
lity (presence) across the lists produced by l1l2FS in the
cross-validation procedure.
Following Ray et al. [4] and Ravetti and Moscato [18],
we used the Test Set AD and the Test Set MCI to verify
the predicting ability of our signature.
Ray et al. adopted a shrunken centroid algorithm and
identified 18 predictors characterizing AD status. Simi-
larly, Ravetti and Moscato considered the dataset and
applied more than 20 different classifiers to achieve a
highly predictive 5-protein signature.
After the feature selection step, for each test set the
test phase consisted in extracting the sub-matrix corre-
sponding to the 21 relevant variables identified in the
training phase and in applying the learned model.
The Test Set AD is composed by samples affected by
either AD or other dementia and by controls. In this
case, our model scored a 7/92 error (see Figure 1), while
Ray and co-authors obtained a 10/92 error and Ravetti
and Moscato an error of ~ 6/92, averaged over all the
methods they applied.
The Test Set MCI is composed by 47 samples corre-
sponding to subjects with MCI as illustrated in Figure
1. In this case, we used the statistical model as a pre-
dictor of outcome, considering the conversion to AD
Figure 1 Proteomic Training and Test (AD and MCI). The Training Set is composed by 43 AD samples and 40 NDC samples. The Test Set AD
is composed by 42 AD samples and 50 non-AD samples (9 NDC and 11 OD). The Test Set MCI is composed by 47 samples diagnosed with a
mild cognitive impairment and with known final follow-up (2-6 years). The Training Set is fed as input to the l1l2FS framework (grey box), which
splits the data in K subsplits (light blue boxes), evaluating the relevant variables and the classification error for each one. Performance of the
classifier is then tested on the Test Set AD and Test Set MCI using only the 21 proteins selected in the training phase. The test error is
decomposed in True Positives (TP), False Negatives (FN), False Positives (FP), True Negatives (TN).
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as benchmark status (follow-up: 2-6 years from MCI
diagnosis). The statistical model scored a 10/47 error,
while Ray and co-authors obtained a 9/47 overall error
and Ravetti and Moscato achieved an average error of
~ 16/47.
Literature characterization
Table 1 reports the 21 relevant genes identified by l1l2FS,
ranked according their stability in terms of the fre-
quency score. Thirteen genes are meaning-fully asso-
ciated to AD, to other brain diseases or to brain-related
processes. The signature completely includes the one of
Ravetti and Moscato [18] and almost completely the one
presented in [4]. Some genes uniquely belong to our sig-
nature: ADIPOQ, MST1, TNFRSF10C, ANGTP1, AGRP
and IL6; with the exception of the latter, the other pro-
teins have never been associated to AD. ADIPOQ
encodes for the adiponectin protein that circulates in
the plasma and it is involved in the metabolic and hor-
monal processes. This protein is unable to cross the
blood-brain barrier but it is able to modify cytokine
expression in the brain endothelial cells [19]; the cyto-
kines are known to be involved in AD. ADIPOQ also
characterizes the pathogenesis of the insulin resistance
[20] that is a common trait of AD patients.
AGRP encodes for a protein homolog to agouti, a
murine protein that regulates the hypothalamic control
of feeding behavior via melanocortin receptor and/or
intracellular calcium regulation. It therefore influences
the weight homeostasis. Kim et al. [21] note that AGRP
stimulates insulin secretion through calcium release in
pancreatic beta cells. Imbalances in insulin and calcium
are well-known risk factors for AD.
ANGPT1 and ANGPT2 contribute to the glucose
metabolism by interacting with VEGF [22] and they are
both indicated to have a prognostic value in adult forms
of malignant brain tumors [23].
TNFR10C encodes for a member of the tumor necro-
sis factor that protects the cells from TRAIL-induced
apoptosis. It is regulated by p53 and it is inducible by
DNA damage. It is not constitutively expressed in the
human brain but its apoptosis-mediating and apoptosis-
blocking receptors are found on neurons, astrocytes and
oligodendrocytes [24].
The same holds for TNFRSF10D, which is involved in
the same KEGG pathways of TNFRSF10C (i.e. apoptosis,
cytokine-cytokine receptor interaction, natural killer cell
mediated cytotoxicity).
MST1 encodes for the macrophage stimulating 1 fac-
tor. MST1, interacting with FOXO1, induces its accu-
mulation in the nucleus leading to cell death, upon
withdrawal of growth factors and neuronal activity [25].
Functional analysis of the signature
Table 2 shows the results of gene set enrichment analy-
sis of the signature using KEGG [26].
The selected proteins are especially involved in the
Signaling Molecules and Interaction and Immune Sys-
tem categories, but also in processes related to the cell
(Cell Growth and Death, Cell Communication, Signal
Transduction). These results underline the role of the
selected genes within pathways already linked to AD:
cytokine-cytokine receptor interaction [2,3,27], hemato-
poietic cell lineage [2,3], apoptosis [2,3,27], pathways
involved in the immune and inflammatory response [2]
and pathways related to Metabolic Diseases [28]. We
also identified pathways not previously associated with
AD: adipocytokine, PPAR signaling pathway, glioma and
pancreatic cancer. We extended the functional analysis
of our signature applying the gene set enrichment pro-
cedure on GO. The results are presented in Additional
file 1. The heatmap plot in Figure 2 visualizes the struc-
tured signature obtained by l1l2FS and postprocessed by
k-means clustering. Such structured representation con-
firmed that the genes belonging to the same clusters,
having highly correlated abundance profiles, are indeed
grouped in the same ontologies or biological pathways
or they are known to interact. For instance, gene set
enrichment in GO showed two gene pairs: GCSF/IL3 in
the positive biological processes and IL8/TNFRSF10D in
the negative biological processes. The heatmap plot in
Figure 2 shows them into two different clusters. The
Table 1 Table of protein signature
Gene symbol (d) Official Gene Symbol Entrez ID Frequency(%)
EGF_1 EGF 1950 100
PDGF-BB_1 PDGFB 5155 100
RANTES_1 CCL5 6352 100
TNFa TNFa 7124 100
GCSF_1 CSF3 1440 100
ICAM-1_1 ICAM1 3383 100
IL-1a IL-1a 3552 90
M-CSF_1 CSF1 1435 90
PARC_1 CCL18 6362 80
Acrp30_1 ADIPOQ 9370 70
ANG-2_1 ANGPT2 285 70
IL-8_1 IL8 3576 60
IL-3_1 IL3 3562 60
IL-11_1 IL11 3589 60
IL-6 R_1 IL6R 3570 50
IGFBP-6_1 IGFBP6 3489 50
MSP-a_1 MST1 4485 50
TRAIL R3_1 TNFRSF10C 8794 40
ANG_1 ANGTP1 284 40
AgRP(ART)_1 AGRP 181 40
TRAIL R4_1 TNFRSF10D 8793 40
The 21 gene signature identified by l1l2FS. The Gene symbol column reports
the corresponding genes following the same nomenclature used by [4]. The
Official Gene Symbol column shows the nomenclature of Entrez-Gene and the
Frequency column shows the cross-validation frequency scores.
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Table 2 Table of the functional analysis made in KEGG for protein signature
KEGG pathway KEGG category n. P
Cytokine-cytokine receptor interaction 14 9.69e-26
Cell adhesion molecules (CAMs) Signaling Molecules and Interaction 1 7.59e-2
Neuroactive ligand-receptor interaction 1 1.67e-1
Hematopoietic cell lineage 7 6.00e-14
Natural killer cell mediated cytotoxicity 4 9.12e-7
Toll-like receptor signaling pathway Immune System 3 2.19e-5
Fc epsilon RI signaling pathway 2 1.01e-3
Leukocyte transendothelial migration 2 2.29e-3
T cell receptor signaling pathway 1 5.57e-2
Apoptosis Cell Growth and Death 5 1.54e-9
MAPK signaling pathway 4 2.21e-5
Jak-STAT signaling pathway Signal Transduction 4 1.90e-6
TGF-beta signaling pathway 1 4.96e-2
Adipocytokine signaling pathway Endocrine System 3 1.13e-5
PPAR signaling pathway 1 4.17e-2
Epithelial cell signaling in Helicobacter pylori infection Infectious Diseases 2 8.05e-4
Gap junction Cell Communication 2 1.33e-3
Focal adhesion 2 6.43e-3
Glioma Cancers 2 6.66e-4
Pancreatic cancer 1 4.42e-2
Type I diabetes mellitus Metabolic Diseases 2 2.96e-4
Type II diabetes mellitus 2 3.26e-4
Regulation of actin cytoskeleton Cell Motility 2 6.89e-3
Enriched pathways of the protein signature resulting from the WebGestalt functional analysis with KEGG. For each pathway, the table reports the pathway name,
its KEGG category, the number of selected genes (n.) and the p-value. The enriched pathways are displayed in boldface.
Figure 2 Heatmap for the proteomic signature. Heatmap representing the abundance of the 21 selected proteins by l1l2FS. The thick black
lines show the gene groups identified with the k-means clustering technique. The samples are divided in two classes: AD and control. The red
and green colors represent high and low abundance respectively. For visualization purposes the expressions have been scaled between 0 and 1.
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enrichment in KEGG provided additional examples. For
instance, EGF and PDGFB were clustered together and
they are both involved in several pathways: cytokine-
cytokine receptor interaction, MAPK signaling pathway,
gap junction, focal adhesion, glioma and regulation of
actin cytoskeleton. TNFa and CSF1 show similar abun-
dance profiles and they are included in the hematopoie-
tic cell lineage and cytokine-cytokine signaling pathways.
These proteins are also known to interact. Similar exam-
ples are: IL3/IL-1a, CSF3/IL-1a, ADIPOQ/AGRP,
TNFRSF10C/TNFRS10D.
Microarray data analysis - GSE1297
Results of the l1l2FS
The l1l2FS procedure applied to the GSE1297 dataset
provided a signature of 12 probesets associated to 11
genes, reported in Table 3. The list corresponds to the
highest value of the correlation parameter μ. In this case
the 10-fold cross-validation error was 17%. Nine of the
11 genes are related to AD, other neurological disorders
or brain functions. It is not straightforward to compare
our results to those in [5], because they applied a Pear-
son correlation test, without providing a classification
error.
Literature characterization
XIST encodes for a transcript not translated in a pro-
tein. Its main role is the X chromosome inactivation
during the early development in mammal females. More
recently, one transcription variant of XIST has been
found expressed in a subset of neurons as part of a
group of gender-specific genes differentially expressed in
some brain regions [29].
The literature describes TAC1 as the encoder for
many hormones that may function as neurotransmitters,
interacting with nerve receptors and smooth muscle
cells.
HSPA1A is a heat shock protein of the Hsp70 family.
It prevents the subsequent aggregation of misfolded pro-
teins and it is instrumental in targeting them for degra-
dation when the above mechanism fails [30]. The
misfolding and the aggregation of proteins are common
characteristics of several neurodegenerative diseases
including AD and Parkinson’s disease, therefore it is
very likely that HSPA1A may also characterize AD.
Heat shock protein DNAJB1 has an increased expres-
sion in the lymphoblastoid cell lines from patients with
bipolar I and II disorders and schizophrenia [31]. It is
also known to modulate the activity of the Hsp70 family
that leads to the translocation of proteins into the mito-
chondria and endoplasmatic reticulum thus affecting the
functions of these organelles [32].
TNC encodes tenascin-C that contributes to the inva-
sive nature of glioblastoma and the majority of high-
grade gliomas [33], to the adhesion of medulloblastoma
[34] and to the malignant transformation of plexiform
neurofibromas [35].
RGS4 belongs to the regulators of G protein signaling
family. A recent paper [36] reports that RGS4 contri-
butes to the regional differences in the coupling of mus-
carinic M1 receptors in AD. The expression of this gene
in the human brain might be spatially and temporally
regulated by alternative promoters, resulting in several
previously unknown isoforms [37]. This may have impli-
cations for the physiological role of RGS4 in some
pathologies of the brain.
Besides being involved in the cannabinoid-induced
central nervous system (CNS) effects, cannabinoid
receptor 1 (CNR1) participates in the development of
insulin resistance in the human skeletal muscle and its
expression is markedly decreased in AD brains [38].
LTF is a major iron-binding protein in milk and body
secretions with an antimicrobial activity. It has several
functions, including regulation of iron homeostasis, host
defense against a broad range of microbial infections,
anti-inflammatory activity, regulation of cellular growth
and differentiation. This protein seems to be up-regu-
lated in AD patients [39].
MCTP1 encodes for a protein integral to the cell
membrane that is involved in the calcium-mediated sig-
naling process. Indeed, the imbalance of calcium is one
of the major AD risk factors.
Functional analysis of the signature
Table 4 and Additional file 2 present the results of the
functional characterization performed in KEGG and GO.
KEGG analysis indicated that these genes are espe-
cially involved in the Signaling Molecules and Interac-
tion KEGG category (ECM-receptor-interaction and
neuroactive ligand-receptor interaction)and in Cell
Table 3 Table of gene expression signature (GSE1297)
Gene symbol (d) Official Gene Symbol Entrez ID Frequency(%)
221728_x_at XIST 7503 100
221729_at COL5A2 1290 100
221730_at COL5A2 1290 100
206552_s_at TAC1 6863 90
200800_s_at HSPA1A 3303 60
200664_s_at DNAJB1 3337 50
201645_at TNC 3371 50
204337_at RGS4 5999 50
212063_at CD44 960 50
213436_at CNR1 1268 50
202018_s_at LTF 4057 40
220122_at MCTP1 79772 40
The 12 probesets signature identified by l1l2FS. The Gene symbol refers to the
Affymetrix probeset ID, the Official Gene Symbol shows the nomenclature of
Entrez-Gene and the Frequency column shows the cross-validation frequency
score.
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Communication and Immune System (cell communica-
tion, focal adhesion, antigen processing and presentation
and hematopoietic cell lineage).
Again, we considered the functional results together
with the structured heatmap, identifying those groups of
probesets with similar expression profiles also involved
in the same pathways or in the same ontologies, see Fig-
ure 3. For instance, CNR1, TAC1 and RGS4 are
involved in the G-protein coupled receptor protein sig-
naling pathway GO process; CNR1 and TAC1 are
involved in the neuroactive ligand-receptor interaction
KEGG pathway. CD44 and TNC share the ECM-recep-
tor interaction pathway. The two probesets referring to
the same gene, COL5A2, were nicely clustered together
in the same group and showed very similar expression
profiles. The last pair is composed by HSPA1 and
DNAJB1 which have similar expression profiles and
belong to the same biological process, i.e. response to sti-
mulus. These proteins are also known to interact [40].
Microarray data analysis - GSE5281
Results of the l1l2FS
Table 5 reports the 39 probesets that formed the second
microarray-based signature, associated with the highest
value of the correlation parameter μ. In this case, the 5-
fold cross-validation error was 5%. Nine of the 39 iden-
tified genes are already associated to AD, other brain
diseases or brain-related processes. As opposed to the
other datasets, the number of well-characterized genes
was low compared to the number of selected genes. A
Table 4 Table of the functional analysis made in KEGG for GSE1297 signature
KEGG pathway KEGG Category n. P
ECM-receptor interaction Signaling Molecules and Interaction 3 2.39e-6
Neuroactive ligand-receptor interaction 2 3.93e-3
Cell Communication Cell Communication 2 5.40e-4
Focal adhesion 2 1.75e-3
MAPK signaling pathway Signal Transduction 1 8.51e-2
Antigen processing and presentation Immune System 1 2.37e-2
Hematopoietic cell lineage 1 2.76e-2
Enriched pathways of the GSE1297 signature resulting from the WebGestalt functional analysis with KEGG. For each pathway, the table reports the pathway
name, its KEGG category, the number of selected genes (n.) and the p-value. The enriched pathways are displayed in boldface.
Figure 3 Heatmap for the GSE1297 signature. Heatmap representing the gene expression of the 12 selected probestes by l1l2FS in the
GSE1297 experiment. The thick black lines show the gene groups identified with the k-means clustering technique. The samples are divided in
two classes: AD and control. The red and green colors represent high and low expression respectively. For visualization purposes the expressions
have been scaled between 0 and 1.
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comparison of the classification results was not feasible
because in [6] the authors used a t-test filtering method,
which is not directly associated to a classification error.
Literature characterization
The somatostatin hormone (SST) is expressed in the
body and a ects the rates of neurotransmission [41].
CXCR4, the chemokine receptor 4, is specific for stro-
mal cell-derived factor-1. This protein is known to be
highly expressed in the neural precursor cells [42], to be
implicated in the inflammation affecting the brain [43]
and, like several others chemokines and their receptors,
to be implicated in AD [44]. This gene is also critical to
the progression of various brain malignancies [45,46].
GFAP, the glial fibrillary acidic protein, encodes one
of the major intermediate filament proteins of mature
astrocytes. Besides its use as a marker to distinguish
astrocytes from other glial cells during development
[47,48], GFAP is expressed in the neurons of hippocam-
pus of AD patients [49-51].
CTSB, the lysosomal cysteine proteinase, is known as
an amyloid precursor protein (APP) secretase and it is
involved in the proteolytic processing of APP. Indeed,
the incomplete proteolytic processing of APP is the
most known and important causative factor in AD [52].
Enkephalin precursor PENK is a neuropeptide hor-
mone that, together with protachykinin A the precursor
of SP, is altered in both dementia and acute neuroin-
flammatory disorders [53].
Finally, the ubiquintin protein ligase E3A (UBE3A) can
be implicated not only in the pathogenesis of Angelman
syndrome but also in the neurodegenerative disorders
involving protein aggregation [54].
Functional analysis of the signature
Table 6 reports the results of the enrichment analysis in
KEGG. We did not find any enriched pathway because
the majority of the selected genes are not yet function-
ally characterized. Nevertheless, some of the involved
pathways had a significant p-value (p-value < 0.05) and,
among them, those in Neurodegenerative Diseases, Sig-
naling Molecules and Interaction and Immune System
are the most significantly connected with AD. The
results of GO enrichment analysis are reported in Addi-
tional file 3.
Integrated functional analysis of the three signatures
First, we proceeded by simply intersecting the three
gene signatures. This procedure identified RGS4,
MCTP1, CD44 and XIST as common between the two
microarray signatures.
Taking a step towards an integrated functional charac-
terization, we compared our results at the functional
level, in order to identify common pathways and/or
ontologies. The integration followed a late integration
schema [55].
The comparison at the pathway level for the KEGG
results is shown in Table 7 and Figure 4. Table 7 pre-
sents three common pathways and several pathways
common between two of the three signatures. Figure 4
illustrates the selected genes and their relation to the
aforementioned pathways. This figure summarizes the
main result of the integrated analysis, highlighting the
common pathways between two signatures, the
Table 5 Table of gene expression signature (GSE5281)
Gene symbol (d) Official Gene Symbol Entrez ID Frequency(%)
202234_s_at SLC16A1 6566 100
205048_s_at PSPH 5723 100
212063_at CD44 960 100
213921_at SST 6750 100
223380_s_at LATS2 26524 100
230629_s_at EP400 57634 100
231735_s_at MALAT1 378938 100
235987_at PRKXP1 441733 100
204142_at ENOSF1 55556 80
212417_at SCAMP1 9522 80
213872_at C6orf62 81688 80
214246_x_at MINK1 50488 80
217028_at CXCR4 7852 80
220122_at MCTP1 79772 80
220182_at SLC25A23 79085 80
221646_s_at ZDHHC11 79844 80
227413_at UBLCP1 134510 80
228697_at HINT3 135114 80
209116_x_at HBB 3043 60
212451_at SECISBP2L 9728 60
216834_at RGS1 5996 60
224588_at XIST 7503 60
228946_at INTU 27152 60
229120_s_at CDC42SE1 56882 60
230748_at SLC16A6 9120 60
1554447_at LOC554203 554203 60
1569110_x_at LOC728613 728613 60
202436_s_at CYP1B1 1545 40
203540_at GFAP 2670 40
204338_s_at RGS4 5999 40
206826_at PMP2 5375 40
211959_at IGFBP5 3488 40
213274_s_at CTSB 1508 40
213791_at PENK 5179 40
214980_at UBE3A 7337 40
227062_at NEAT1 283131 40
229676_at MTPAP 55149 40
229793_at ASAH2B 653308 40
235060_at LOC100190986 100190986 40
The 39 probesets signature identified by l1l2FS. The Gene symbol refers to the
Affymetrix probeset ID, the Official Gene Symbol shows the nomenclature of
Entrez-Gene and the Frequency column shows the cross-validation frequency
score.
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pathways shared by all signatures and also those known
to be related to AD or other brain diseases. The shared
pathways were: hematopietic cell lineage, neuroactive
ligand-receptor interaction and MAPK signaling
pathways.
In the GO integrated analysis (see Additional files) it
is clear that the annotation for the protein dataset is
richer than the other two datasets, hence the overlap
takes place at a somewhat high level in the GO hierar-
chy. For instance, in the BP domain, the overlap reaches
down to the cellular process node. If we consider two
signatures at a time, we note slightly more specific com-
mon nodes. In both the protein and GSE1297 signa-
tures, the following ontologies are enriched:
extracellular region and extracellular region part in the
CC domain and response to stimulus and response to
biotic stimulus for the BP domain. If we consider the
protein and GSE5281 signatures, the common enriched
nodes are negative regulation of biological process and
negative regulation of cellular process.
Discussions
In this section we will clarify the reasons behind the
choice of the datasets and we will illustrate more exten-
sively the results in the context of identifying common
functional pathways possibly harboring marker genes.
We primarily chose to study heterogeneous datasets to
deal with the multifactorial nature of AD. Indeed, AD
affects different brain areas [7] with various lesions: the
most evident are deposits of beta amyloid and tangles of
hyperphosphorylated tau proteins, together with a
marked loss of neurons mostly in the neocortex and hip-
pocampus [2,3]. Moreover, AD impacts many molecular
levels causing the depletion of neurotrophins and neuro-
transmitters, dysfunctions affecting the mitochondria,
disturbances affecting the metabolism of cholesterol and
insulin, inflammation and loss of calcium regulation [3].
Hence, we analyzed data measuring the effects of AD at
different molecular levels, i.e. DNA and proteins.
The protein dataset mainly measures the abundance of
a specific class of signaling proteins while the two
Table 6 Table of the functional analysis made in KEGG for GSE5281 signature
KEGG pathway KEGG Category n. P
Glycine, serine and thereonine Amino Acid Metabolism 1 3.20e-2
Tryptophan metabolism 1 5.88e-2
Metabolism of xenobiotics by cytochrome P450 Xenobiotics Biodegradation and Metabolism 1 4.23e-2
Neurodegenerative Diseases Neurodegenerative Diseases 1 2.54e-2
Prion disease 1 9.04e-3
MAPK signaling pathway 1 1.83e-1
Cytokine-cytokine receptor interaction 1 1.68e-1
ECM-receptor interaction Signaling Molecules and Interaction 1 6.02e-2
Neuroactive ligand-receptor migration 1 1.96e-1
Axon guidance Development 1 8.77e-2
Antigen processing and presentation 1 5.31e-2
Hematopoietic cell lineage Immune System 1 6.17e-2
Leukocyte transendothelial migration 1 8.14e-2
Enriched pathways of the GSE5281 signature resulting from the WebGestalt functional analysis with KEGG. For each pathway, the table reports the pathway
name, its KEGG category, the number of selected genes (n.) and the p-value. The enriched pathways are displayed in boldface.
Table 7 Table of the integrated functional analysis for the three signatures
KEGG pathway KEGG Category Protein GSE1297 GSE5281
Cytokine-cytokine receptor interaction ● o
Neuroactive ligand-receptor migration Signaling Molecules and Interaction o o o
ECM-receptor interaction ● o
Antigen processing and presentation o o
Hematopoietic cell lineage Immune System ● o o
Leukocyte transendothelial migration o o
MAPK signaling pathway Signal Transduction ● o o
Focal adhesion Cell Communication o o o
KEGG pathways common between two or three signatures. The table reports the pathway name, its KEGG category and the signatures IDs. The enriched
pathways are identified with filled circles, whereas empty circles are associated to not enriched pathways.
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microarray datasets quantify the expression of nearly the
entire genome. Nevertheless, we deemed the integrated
functional analysis feasible because there exists an over-
lapping set of measured genes across the three datasets.
This assumption was also validated a posteriori, because
the number of common pathways between the microar-
ray datasets was comparable with the number of com-
mon pathways between the protein dataset and each
microarray set (see Table 7). Despite the blood protein
data are heavily shifted towards cytokine measurements,
the overall results were unbiased.
The integration of results from different datasets cor-
responds to an in silico validation phase. A consistency
assessment of the results across datasets is fundamental
in verifying their reliability and in deciding for a further
biological validation step [56].
The integrated functional analysis led to very promis-
ing results: most of the significant identified genes and
pathways are likely related to AD and worth further
investigation.
The classification performances of the protein dataset
were equivalent or slightly better than those achieved by
[4], who provided the dataset, and by [18], who later
analyzed it. The l1l2FS protein signature was comparable
with those in [4,18], completely including the latter and
differing on only three genes with the former. Seven
genes were uniquely selected by l1l2FS, namely: IL6R,
MST1, TNFRSF10C, ANGTP1, ADIPOQ and AGRP.
Aside for IL6R, they have never been associated to AD.
Both ADIPOQ and AGRP are involved in the same
KEGG pathway of TNFa, which is a protein considered
to be a probable prognostic factor of AD and recently
mentioned in several works [2,4,18]. This pathway,
namely adipocytokine signaling, also comprises PGC-1a,
a protein that is a potential target for treating type II
diabetes (it is indeed involved in the regulation of
Figure 4 Integrated functional analysis for the three signatures. Relevant KEGG pathways, including: the enriched pathways, those common
between two or more signatures and also those related to AD or other brain diseases (in boldface the pathways common to all the signatures).
Within each pathway we report the selected genes color-coded according to the signature: purple for the protein dataset, pink for the GSE1297
dataset and dark green for GSE5281 dataset. KEGG categories are displayed in uppercase.
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glucose metabolism) and that has been shown to
decrease the hyperglycemic-mediated production of
beta-amyloid [57]. In addition, the work of Gavrila et al.
[58] suggested the use of AGRP as useful peripheral
marker of metabolism change. ANGPT1 as well as
ANGPT2 encodes for angiopoietins, relevant for vascu-
lar development, angiogenesis and lymphogenesis. Both
proteins were studied in patients with type II diabetes
mellitus and found to be related to VEGF, glycemic con-
trol, endothelial damage/dysfunction and atherosclerosis
[22]. In particular, ANGPT1 has a role in the pathologi-
cal vascularization of malignant astrocytomas [59] and
the balance between ANGPT1 and ANGPT2 has prog-
nostic value in patients with primary glioblastoma multi-
forme [23]. The involvement of these proteins in the
glucose metabolism as well as in the pathogenesis of
brain tumors makes them interesting for further investi-
gation with in vitro techniques.
The functional analysis revealed pathways previously
unrelated to AD, e.g. adipocytokine, PPAR signaling
pathway and other related to different diseases, such as
glioma and pancreatic cancer. Despite having a signifi-
cant p-value, these three pathways were not enriched,
because of the small number of genes belonging to the
signature, see Table 2.
The analysis of GSE1297 led to the identification of
TAC1. TAC1 encodes for substance P (SP), neurokinin
A, neuropeptide K and neuropeptide gamma. SP sti-
mulates human peripheral blood monocytes to produce
in ammatory cytokines including IL12, IL6, IL1 and
TNFa, all belonging to the protein signature except for
the former two. Recently, [53] highlighted the altera-
tion of the highly correlated PENK and SP in both
dementia and acute neuroinflammatory disorders. SP is
a neuropeptide that is widely distributed in the central
and peripheral nervous systems and it has a well-estab-
lished role as neurotransmitter and as neuroimmunor-
egulator [60]. SP and its receptor NK1R are involved
in inflammation and neurological disorders within the
CNS [61,62]. PENK also belonged to the GSE5281 sig-
nature. At the functional level, the analysis selected the
ECM-receptor-interaction and the neuroactive ligand-
receptor interaction pathways, both belonging to the
Signaling Molecules and Interaction KEGG category,
which is related to AD [4].
In the GSE5281 signature, SST and UBE3A are rele-
vant for further studies. SST is an important regulator
of the endocrine system and it is likely to have a role in
the regulation of ADIPOQ, AGRP and TNFa, that l1l2FS
selected in the protein signature and that were assigned
to enriched KEGG pathways within the Endocrine sys-
tem category. SST also affects the rates of neurotrans-
mission in the CNS and proliferation of both normal
and tumorigenic cells. Associations of this gene with
AD are already suggested [63-66], even if its exact role
in the disease is not clear yet. SST is also known to be
co-transported with SP, one of the products of TAC1
mentioned above.
UBE3A functions as a cellular quality control ubiqui-
tin ligase. Since AD is characterized by the accumula-
tion of amyloid-beta and tau peptides, this protein could
be a good candidate for investigation because it partici-
pates to the ubiquitin protein degradation system, with
the main function of breaking down the non-functional
proteins.
The l1l2FS analysis performed separately on the micro-
array datasets scored low cross-validation errors and
revealed 4 common significant genes: RGS4, MCTP1,
CD44 and XIST. Besides RGS4 [36], the other genes
have never been associated with AD but, as noted in lit-
erature characterization, they are very likely to play a
role in the disease.
The integrated functional analysis showed pathways
that are common across two or three of the signatures,
see Table 7 and Figure 4. Such pathways are already
related to AD and they belong to the Signaling Mole-
cules and Interaction, Immune System, Signal Transduc-
tion and Cell Communication KEGG categories. In
particular, these pathways are involved in the immune
system and inflammation (cytokine-cytokine receptor
interaction, antigen processing and presentation, hemato-
poietic cell lineage, leukocyte transendothelial migration),
in the nervous system and related diseases (neurodegen-
erative disorders, neuroactive ligand-receptor interaction,
prion disease and axon guidance), in cell proliferation,
differentiation and migration and also in the mainte-
nance of the structure and function of one cell line or
tissue (MAPK signaling and ECM-receptor interaction).
The combined analysis of the three signatures led to
the identification of common probesets between the two
microarray signatures and of a meaningful functional
overlap among the three signatures. The statistical
method adopted for the analysis allowed for the selec-
tion of genes that are already known to be related with
AD or to be expressed in the brain. This strengthened
the hypothesis that the remaining selected genes might
be relevant for further studies, especially because the
results were obtained without using any prior knowledge
on the subject. Despite the very convincing results, we
are aware of some limitations that affected our work
and that should be overcome in the future. From the
data viewpoint, we coarsely divided the available samples
in two broad classes (healthy and diseased) but it would
be more accurate to separately consider the three AD
stages (incipient, moderate, severe) versus controls.
More-over, when dealing with the GSE5281 data, we
could discard those samples extracted from the visual
cortex that seems to be spared by AD [6]. On the
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computational side, the l1l2FS framework has the advan-
tage of being correlation-aware and multivariate. Unfor-
tunately, the algorithm itself and the double loop of
nested cross-validation procedures heavily demand com-
putational power, in contrast to more standard techni-
ques, such as t-test, that are easier to run even by non-
specialists. Nonetheless, the computational burden can
be significantly reduced by running the statistical frame-
work on distributed computing facilities, such as clus-
ters, grids or cloud computing.
Conclusion
Gene signatures are the first indispensable step towards
the identification of genes and proteins highly related
with disease and belonging to pathogenic pathways.
Indeed, in the context of AD, there is a urgent need to
improve its molecular characterization to establish novel
therapeutic targets and reliable biomarkers.
By applying l1l2FS on three AD datasets, we defined
gene signatures with good discriminative properties for
the classification of diseased and healthy subjects. Our
work, focused on the functional characterization of
potentially meaningful AD genes, revealed 21 genes in
the protein dataset [4], 11 and 39 genes in the GSE1297
[5] and GSE5281 [6] microarray datasets respectively.
Each signature was robust from the statistical viewpoint
and it was associated to a low cross-validation error.
Some of the selected genes are already known to be
involved in AD; others have never been associated with
the disease but the current biological knowledge sug-
gests their possible correlation with AD. Specifically, the
first group comprises TNFa, IL6R, IL-1a, GFAP,
CXCR4, CTSB, SST, LTF, CNR1, RGS4 and the second
is formed by ADIPOQ, AGRP, HSPA1A, PENK,
UBE3A, TAC1, TNFRSF10C and ANGPT1.
The functional analysis of the signatures confirmed the
validity of the results, identifying pathways that are biolo-
gically meaningful and related with AD, see Figure 4.
The integrated functional analysis revealed three
overlapping pathways: hematopoietic cell lineage, neu-
roactive ligand-receptor interaction and MAPK signal-
ing pathways. The validity of our procedure was also
confirmed at the functional level, in fact the common
pathways are already mentioned in the literature as
important for AD [2,3].
The use of l1l2FS as core algorithm for feature selec-
tion allowed for the identification of relevant and corre-
lated genes. Therefore those genes not included in
common pathways and still unmentioned in the litera-
ture could play a role in the pathogenesis of the disease.
In the near future, we plan to extend the analysis in
order to include more available domain knowledge. We
are currently working on designing methods that expli-
citly use prior knowledge on the subject, to drive the
feature selection step for example adopting filtering
techniques [15] or designing appropriate kernel func-
tions [56,67]. We also plan to integrate heterogeneous
data from different techniques (Chip-on-Chip, SNP,




The protein dataset of Ray and co-authors [4] is a col-
lection of 259 plasma samples from individuals with
presymptomatic to late-stage AD and from various con-
trols. The abundance of 120 well-known signaling pro-
teins was measured for each sample with the filtered-
based arrayed sandwich ELISA. The data-set is available
online, already normalized and subdivided in four
groups: the Training Set, composed by 43 AD samples
and 40 nondemented control (NDC) samples; the Test
Set AD, composed by 42 AD, 39 NDC and 11 other
dementia (OD) samples; the Test Set MCI, composed by
47 MCI samples with follow-up (2-6 years from MCI
diagnosis); the OND and RA patient set, composed by
21 other neurological disease (OND) and 16 rheumatoid
arthrithis (RA) samples. The latter dataset was excluded
from our analysis because it did not contain any AD
data. The remaning test sets that presented more than
two classes were considered as binary problems: AD
versus not-AD.
The other datasets are stored in the GEO repository:
GSE1297 of Blalock et al. [5] and GSE5281 of Liang et
al. [6]. The first consisted of 22 AD samples and 9 con-
trols retrieved from the hippocampal brain region. The
gene expressions were measured on the Affymetrix HG-
U133A platform. The second dataset was measured on
the Affymetrix HG-U133 Plus2.0 platform and it was
composed by 87 AD late onset samples and 74 controls
on six different brain regions originating from the same
subject: entorhinal cortex, hippocampus, medial tem-
poral gyrus, posterior cingulate, superior frontal gyrus
and primary visual cortex. Some of the samples origi-
nated from the same subject, but we did not take expli-
citly into account this information. The statistical
framework treats those samples as if they belonged to
different subjects. For both microarray datasets, the
gene expressions were extracted from the. CEL files and
normalized using the Robust Multichip Average method
[68] by running an R [69] script, based on the aroma
package.affymetrix [70] http://www.aroma-project.org.
Feature selection framework
l1l2FS is a regularization method capable to select subsets
of discriminative genes. The algorithm can be tuned to
give a minimal set of discriminative genes or larger sets
including correlated genes. The method is based on the
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optimization principle presented in [8] and further
developed and studied in [9,71]. First we fix some nota-
tion and then we explain the idea behind the algorithm.
Assume we are given a collection of n subjects, each
represented by a d-dimensional vector x of measure-
ments (e.g. the gene expression or the protein abun-
dance vector). Each sample is also associated with a
binary label y, assigning it to a class (e.g. AD or control).
The dataset is therefore represented by a n × d matrix
X, where d >>n and Y is the n-dimensional labels vector.
The l1l2FS with double optimization algorithm looks for
a linear model f(x) = bx, whose sign gives the classifica-
tion rule that can be used to associate a new sample to
one of the two classes. The offset is zero, since we nor-
malize the X matrix to have zero mean. Note that the
vector of weights b is forced to be a sparse vector, that
is some of its entries are zero, then some variables (pro-
besets or proteins) will not contribute in building the
estimator f(x). The weight vector b is found by minimiz-
ing the naïve elastic net functional:
||Y − βX||22 + τ ||β||1 + μ||β||22
where the least square error is penalized with the l1
and l2 norm of the coefficient vector b. The least square
term ensures fitting of the data whereas adding the two
penalties allows to avoid over-fitting. The role of the
two penalties is different, the l1 term (sum of absolute
values) enforces the solution to be sparse, the l2 term
(sum of the squares) preserves correlation among the
variables. The solution of this step, computed through
the simple iterative softthresholding [72], is followed by
a second optimization, namely regularized least squares
(RLS):
||Y − βX||22 + λ||β||22
to estimate the classifier on the selected features and
to improve the classification performance [73]. The
training for selection and classification requires the
choice of the regularization parameters for both l1l2FS
regularization and RLS denoted with τ* and l*, respec-
tively. In fact, the model selection and statistical signifi-
cance assessment are performed within two nested K-
fold cross-validation loops, similarly to [14,74]. When a
separate set of new data, i.e. a test set, is difficult to
gather because of cost or time issues, cross-validation
represents the most common solution to achieve an
accurate estimate of prediction error. In K-fold cross-
validation, the available data are split into K roughly
equal-sized parts. For each k-th part, a model is trained
on the other K - 1 (training) and a prediction error is
evaluated using the fitted model to predict the outcome
on the k-th part (test). The estimated prediction error is
the combination (usually the average) of the K estimated
errors. Specifically, we emploied stratified cross-valida-
tion, where the folds are selected so that the mean
response value is approximately equal in all the folds. In
the case of binary classification, this means that each
fold contains roughly the same proportions of the two
types of class labels. Stratified cross-validation is particu-
larly useful to avoid unbalances between Type I (False
Positive - FP) and Type II (False Negative - FN) errors.
Being interested in a comprehensive list of relevant
variables, we fixed our attention on the lists obtained
with the highest values for the correlation parameter μ
(μ = 1). The framework was implemented in Python,
based on the L1L2Py library http://slipguru.disi.unige.it/
Research/L1L2Py.
The statistical framework described above provides a
set of K lists of selected variables, therefore it it is neces-
sary to choose an appropriate criterion [75] in order to
assess a common list of relevant variables (probesets or
proteins, in our case). We based ours on the absolute
frequency, i.e. we decided to promote as relevant vari-
ables the most stable probesets across the lists. The
threshold we used to select the final lists was chosen
according to the slope variation of the number of
selected genes vs. frequency (plot not shown), its value
being 40%. In this way we managed to cut out those
variables that were not stable across the cross-validation
lists, similarly to the procedure adopted in [14].
We also visualized the signatures in heatmap plots in
order to devise the modules of correlated variables
within the signatures by applying a k-means clustering
procedure, with the aim of enhancing the genes with
correlating expressions [76]. We used the correlation
distance and set the number of clusters according to the
dimensionality of the minimal list that is the list selected
by l1l2FS when the correlation parameter is set to the
minimum value of μ.
Functional Analysis
For the functional analysis of the signatures we used the
online gene set analysis toolkit WebGestalt [77] http://
bioinfo.vanderbilt.edu/webgestalt/.
This online toolkit performs the gene set enrichment
in KEGG and GO and identifies the most relevant path-
ways and ontologies in the signatures. GO is a database
of controlled vocabularies (ontologies) that describes
gene products in terms of their associated domains, that
are biological process (BP), cellular component (CC)
and molecular function (MF), in a species independent
manner. GO is structured as a directed acyclic graph
where each term has a defined relationship to one or
more terms in the same domain and sometimes to other
domains. The most common visual representation of
GO is a graph where the relations among the ontologies
(nodes) are represented by connecting lines (arcs).
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KEGG is a repository that stores the higher-order sys-
temic behaviors of the cell and the organism from geno-
mic and molecular information. It is an integrated
database resource consisting of 16 main databases,
broadly categorized into systems information, genomic
information, and chemical information. All the available
KEGG pathways have been biologically validated before
publishing. Both for KEGG and GO, we selected the
WebGestalt human genome as reference set, p-value ≤
0.05 as level of significance, 3 as the minimum number
of genes and the default Hypergeometric test as statisti-
cal method. Medline [11] was used to retrieve the avail-
able prior knowledge on the genes from the current
literature.
Additional material
Additional file 1: Ontologies for the protein signature. Results of
WebGestalt analysis of the gene set enrichment made for the 21 protein
signature in GO. The enriched ontologies are marked in red color. The
most significant ontologies in MF are associated to the selected
cytokines: some have chemokines activity, some belong to the
hematopoietin/interferon class, some have a growth factor activity and
others are coupled with the G-proteins. The most enriched process in
the BP domain is cell communication, that is connected to signal
transduction. More general processes follow, like regulation of cellular
processes, of physiological processes and of cellular physiological
processes. It is interesting to observe that these general biological
processes present both positive and negative regulation, having only IL3
as common gene. IL3 is a potent growth promoting cytokine involved in
several activities like cell growth, differentiation and apoptosis. IL3
possesses neurotrophic activity and it is associated with neurological
disorders like schizophrenia.
Additional file 2: Ontologies for the GSE1297 signature. Results of
WebGestalt analysis of the gene set enrichment made for the GSE1297
signature in GO. The enriched ontologies are marked in red color. The
GO enrichment is not associated to a large subgraph, as in the protein
signature analysis, because not all the genes are functionally
characterized. The CC domain shows that the gene products of this
signature are mainly located in the extracellular region, probably because
they are involved in the response to stimulus process, that it is
subsequently propagated inside the cell trough the G-protein coupled
receptor protein signaling pathway.
Additional file 3: Ontologies for the GSE5281 signature. Results of
WebGestalt analysis of the gene set enrichment made for the GSE5281
signature in GO. The enriched ontologies are marked in red color.
Similarly to the GSE1297 analysis, the GO subgraph associated to this
signature is not large because of the scarce functionally characterizion of
its genes.
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